Biochemical Pharmacology 79 (2010) 1081–1082

Contents lists available at ScienceDirect

Biochemical Pharmacology

journal homepage: www.elsevier.com/locate/biochempharm

Corrigendum

Corrigendum to "Involvement of sphingosine-1-phosphate and $S1P_1$ in angiogenesis: Analyses using a new $S1P_1$ antagonist of non-sphingosine-1-phosphate analog" [Biochem. Pharmacol. 77 (2009) 1011–1020]

Kiyoaki Yonesu [a,*], Yumi Kawase [a], Tatsuya Inoue [b], Nana Takagi [c], Jun Tsuchida [d], Yoh Takuwa [e], Seiichiro Kumakura [c], Futoshi Nara [a]

[a] Exploratory Research Laboratories II, Daiichi Sankyo Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan
[b] Biological Research Laboratories II, Daiichi Sankyo Co., Ltd., Japan
[c] Biological Research Laboratories III, Daiichi Sankyo Co., Ltd., Japan
[d] Intellectual Property Department, Daiichi Sankyo Co., Ltd., Japan
[e] Department of Physiology, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan

The Publisher regrets that in the above article the journal names in the reference list was typeset incorrectly. The corrected reference list is now reproduced below.

Further reading

[1] Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995;73:333–46.
[2] Zygmunt M, Herr F, Münstedt K, Lang U, Liang OD. Angiogenesis and vasculogenesis in pregnancy. Eur J Obstet Gynecol Reprod Biol 2003;110(Suppl. l):S10–8.
[3] Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–6.
[4] Folkman J. Angiogenesis and its inhibitors. Important Adv Oncol 1985;42–62.
[5] Sebag J, McMeel JW. Diabetic retinopathy. Pathogenesis and the role of retina-derived growth factor in angiogenesis. Surv Ophthalmol 1986;30:377–84.
[6] Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992;51:919–25.
[7] Robinson SC, Coussens LM. Soluble mediators of inflammation during tumor development. Adv Cancer Res 2005;93:159–87.
[8] Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, et al. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 2008;123:2031–40.
[9] Herman WH, Teutsch SM, Sepe SJ, Sinnock P, Klein R. An approach to the prevention of blindness in diabetes. Diabetes Care 1983;6:608–13.
[10] Kohner EM, Barry PJ. Prevention of blindness in diabetic retinopathy. Diabetologia 1984;26:173–9.
[11] Danis RP, Ciulla TA, Criswell M, Pratt L. Anti-angiogenic therapy of proliferative diabetic retinopathy. Expert Opin Pharmacother 2001;2:395–407.
[12] Simó R, Carrasco E, García-Ramírez M, Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2006;2:71–98.
[13] Szekanecz Z, Koch AE. Update on synovitis. Curr Rheumatol Rep 2001;3:53–63.
[14] Jenkins JK, Hardy KJ, McMurray RW. The pathogenesis of rheumatoid arthritis: a guide to therapy. Am J Med Sci 2002;323:171–80.
[15] Wang F, Van Brocklyn JR, Hobson JP, Movafagh S, Zukowska-Grojec Z, Milstien S, et al. Sphingosine 1-phosphate stimulates cell migration through a G_i-coupled cell surface receptor. Potential involvement in angiogenesis. J Biol Chem 1999;274:35343–50.
[16] Lee OH, Kim YM, Lee YM, Moon EJ, Lee DJ, Kim JH, et al. Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun 1999;264:743–50.
[17] Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 1998;279:1552–5.
[18] Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, et al. International union of pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 2002;54:265–9.
[19] Hla T, Maciag T. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J Biol Chem 1990;265:9308–13.
[20] Kon J, Sato K, Watanabe T, Tomura H, Kuwabara A, Kimura T, et al. Comparison of intrinsic activities of the putative sphingosine 1-phosphate receptor subtypes to regulate several signaling pathways in their cDNA-transfected Chinese hamster ovary cells. J Biol Chem 1999;274:23940–7.
[21] Okamoto H, Takuwa N, Yokomizo T, Sugimoto N, Sakurada S, Shigematsu H, et al. Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3. Mol Cell Biol 2000;20:9247–61.
[22] Rosenfeldt HM, Hobson JP, Maceyka M, Olivera A, Nava VE, Milstien S, et al. EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration. FASEB J 2001;15:2649–59.
[23] Igarashi J, Erwin PA, Dantas AP, Chen H, Michel T. VEGF induces $S1P_1$ receptors in endothelial cells: implications for cross-talk between sphingolipid and growth factor receptors. Proc Natl Acad Sci USA 2003;100:10664–9.

DOI of original article: 10.1016/j.bcp.2008.12.007
* Corresponding author. Tel.: +81 3 3680 0151; fax: +81 3 5696 8926.
E-mail address: yonesu.kiyoaki.t8@daiichisankyo.co.jp (K. Yonesu).

0006-2952/$ – see front matter
doi:10.1016/j.bcp.2009.11.013

[24] Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999;99:301–12.
[25] Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000;106:951–61.
[26] Chae SS, Paik JH, Allende ML, Proia RL, Hla T. Regulation of limb development by the sphingosine 1-phosphate receptor $S1P_1$/EDG-1 occurs via the hypoxia/VEGF axis. Dev Biol 2004;268:441–7.
[27] Nishigaki T, Hanaka S, Kingston RE, Handa H. A specific domain of the adenovirus EIV promoter is necessary to maintain susceptibility of the integrated promoter to EIA transactivation. Mol Cell Biol 1988;8:353–60.
[28] Im DS, Clemens J, Macdonald TL, Lynch KR. Characterization of the human and mouse sphingosine 1-phosphate receptor, $S1P_5$ (Edg-8): structure–activity relationship of sphingosine1-phosphate receptors. Biochemistry 2001;40:14053–60.
[29] Ringold G, Dieckmann B, Lee F. Co-expression and amplification of dihydrofolate reductase cDNA and the *Escherichia coli* XGPRT gene in Chinese hamster ovary cells. J Mol Appl Genet 1981;l:165–75.
[30] Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem 1998;273:23722–8.
[31] Yatomi Y, Ruan F, Ohta J, Welch RJ, Hakomori S, Igarashi Y. Quantitative measurement of sphingosine 1-phosphate in biological samples by acylation with radioactive acetic anhydride. Anal Biochem 1995;230:315–20.
[32] Davaille J, Gallois C, Habib A, Li L, Mallat A, Tao J, et al. Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway. J Biol Chem 2000;275:34628–33.
[33] Im DS, Heise CE, Ancellin N, O'Dowd BF, Shei GJ, Heavens RP, et al. Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J Biol Chem 2000;275:14281–6.
[34] Gong J, Strong JA, Zhang S, Yue X, DeHaven RN, Daubert JD, et al. Endomorphins fully activate a cloned human mu opioid receptor. FEBS Lett 1998;439:152–6.
[35] Rikitake Y, Hirata K, Kawashima S, Ozaki M, Takahashi T, Ogawa W, et al. Involvement of endothelial nitric oxide in sphingosine-1-phosphate-induced angiogenesis. Arterioscler Thromb Vasc Biol 2002;22:108–14.
[36] Nakamura T, Yonesu K, Mizuno Y, Suzuki C, Sakata Y, Takuwa Y, et al. Synthesis and SAR studies of a novel class of $S1P_1$ receptor antagonists. Bioorg Med Chem 2007;15:3548–64.
[37] Waeber C, Blondeau N, Salomone S. Vascular sphingosine-1-phosphate $S1P_1$ and $S1P_3$ receptors. Drug News Perspect 2004;17:365–82.
[38] Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, Wu YP, et al. The sphingosine-1-phosphate receptors $S1P_1$, $S1P_2$, and $S1P_3$ function coordinately during embryonic angiogenesis. J Biol Chem 2004;279:29367–73.
[39] Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis assays: a critical overview. Clin Chem 2003;49:32–40.
[40] Herr DR, Grillet N, Schwander M, Rivera R, Müller U, Chun J. Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of $S1P_2$. J Neurosci 2007;27:1474–8.
[41] Kono M, Belyantseva IA, Skoura A, Frolenkov GI, Starost MF, Dreier JL, et al. Deafness and stria vascularis defects in $S1P_2$ receptor-null mice. J Biol Chem 2007;282:10690–6.
[42] Ishii I, Friedman B, Ye X, Kawamura S, McGiffert C, Contos JJ, et al. Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP_{B3}/EDG-3. J Biol Chem 2001;276:33697–704.
[43] Samolov B, Steen B, Seregard S, van der Ploeg I, Montan P, Kvanta A. Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. Exp Eye Res 2005;80:159–66.
[44] Azkur AK, Kim B, Suvas S, Lee Y, Kumaraguru U, Rouse BT. Blocking mouse MMP-9 production in tumor cells and mouse cornea by short hairpin (sh) RNA encoding plasmids. Oligonucleotides 2005;15:72–84.
[45] Lee S, Zheng M, Kim B, Rouse BT. Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J Clin Invest 2002;110:1105–11.
[46] Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992;175:1135–8.
[47] Oliver SJ, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 1994;157:291–9.
[48] Grosios K, Wood J, Esser R, Raychaudhuri A, Dawson J. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm Res 2004;53:133–42.
[49] Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006;9:225–38.
[50] Chae SS, Paik JH, Furneaux H, Hla T. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest 2004;114:1082–9.
[51] LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Cell 2006;66:221–31.
[52] Schmid G, Guba M, Ischenko I, Papyan A, Joka M, Schrepfer S, et al. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J Cell Biochem 2007;101:259–70.
[53] Jo E, Sanna MG, Gonzalez-Cabrera PJ, Thangada S, Tigyi G, Osborne DA, et al. $S1P_1$-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 2005;12:703–15.
[54] Davis MD, Clemens JJ, Macdonald TL, Lynch KR. Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem 2005;280:9833–41.
[55] Sanna MG, Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, Matheu MP, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral $S1P_1$ antagonist *in vivo*. Nat Chem Biol 2006;2:434–41.